Post-marketing surveillance for the safety of the 9-valent human papillomavirus vaccine: a retrospective real-world study in China
Background The 9-valent human papillomavirus (9vHPV) vaccine was introduced in China in 2018. This study was conducted to monitor the occurrence of new-onset autoimmune diseases (AIs) in Chinese women vaccinated with the 9vHPV vaccine and adverse pregnancy outcomes in infants born to mothers with in...
Saved in:
Main Authors: | Ruogu Meng (Author), Rui Ma (Author), Jianmei Wang (Author), Peipei Liu (Author), Zuoxiang Liu (Author), Bingjie He (Author), Zhike Liu (Author), Yu Yang (Author), Siyan Zhan (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Post-marketing study design to evaluate the effectiveness of the 9-valent and 4-valent HPV vaccines on serious HPV-related cervical disease in China
by: Yu Yang, et al.
Published: (2024) -
Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine: Comment
by: Hinpetch Daungsupawong, et al.
Published: (2024) -
Active Surveillance of Adverse Events Following Human Papillomavirus Vaccination: Feasibility Pilot Study Based on the Regional Health Care Information Platform in the City of Ningbo, China
by: Liu, Zhike, et al.
Published: (2020) -
Extended surveillance to assess safety of 9-valent human papillomavirus vaccine
by: Maria E. Sundaram, et al.
Published: (2022) -
Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine in individuals aged 16-26 years in Chongqing, China
by: Yuan-yuan Zhang, et al.
Published: (2023)